Anne W Tann1, Bin S Teh2, Sarah B Scarboro3, Gary D Lewis1, Maria E Bretana4, Porshea C Croft3, Yuval Raizen5, E Brian Butler6, Ryan S Kim7, Patricia Chevez-Barrios8, Amy C Schefler9. 1. Department of Radiation Oncology, University of Texas Medical Branch, Galveston, Texas; Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas. 2. Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas; Department of Radiation Oncology, Houston Methodist Hospital, Weill Cornell Medicine, Houston, Texas. Electronic address: bteh@houstonmethodist.org. 3. Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas. 4. Retina Consultants of Houston, Houston, Texas. 5. Oncology Consultants, Houston, Texas. 6. Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas; Department of Radiation Oncology, Houston Methodist Hospital, Weill Cornell Medicine, Houston, Texas. 7. Retina Consultants of Houston, Houston, Texas; McGovern Medical School at The University of Texas Health Science Center, Houston, Texas. 8. Ophthalmology, Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas; Pathology and Laboratory Medicine, Weill Cornell Medicine, Houston, Texas; Blanton Eye Institute, Houston Methodist Hospital, Weill Cornell Medicine, Houston, Texas. 9. Retina Consultants of Houston, Houston, Texas; Blanton Eye Institute, Houston Methodist Hospital, Weill Cornell Medicine, Houston, Texas.
Abstract
PURPOSE: To report early outcomes of patients with uveal melanoma treated with Eye Physics iodine-125 episcleral plaque therapy using modern biopsy techniques and intraoperative ultrasound guidance at our institution. METHODS AND MATERIALS: A retrospective chart review was conducted for 48 consecutive patients with uveal melanoma who were treated with Eye Physics plaque brachytherapy performed by 1 ocular oncologist. All patients underwent intraoperative ultrasound for image guidance of plaque placement. A dose of 85 Gy was prescribed to the apical height of the tumor or 5 mm from the inner sclera, whichever was greater. Forty-five patients underwent biopsy. Visual acuity, complication data, and recurrence rates were recorded. RESULTS: Median age at presentation was 63.0 years (range, 19-86 years). Median follow-up was 21.6 months. Median tumor apical height was 3.3 mm (range, 1.8-11.5 mm). Median dose at apex for tumor height >5 mm was 85.0 Gy and 142.5 Gy for tumor height ≤5 mm. Mean percent decrease in tumor height from baseline at 12, 24, and 36 months was 39.6%, 51.8%, and 53.8%, respectively. At 24 months, 19/23 (82.6%) patients maintained vision within 3 lines of baseline visual acuity. Twelve patients developed radiation retinopathy, 6 of whom were treated with anti-vascular endothelial growth factor therapy in the context of a clinical trial. No patients to date have local failure. Three patients are alive with confirmed hepatic metastases. CONCLUSIONS: We reported 0% early local failure rate and steady reduction in tumor height in 48 patients with uveal melanoma, ranging from small to large size, who were treated with Eye Physics iodine-125 episcleral plaque therapy using intraoperative ultrasound guidance. This promising result emphasizes the importance of image guided brachytherapy with intraoperative ultrasound at the time of plaque placement.
PURPOSE: To report early outcomes of patients with uveal melanoma treated with Eye Physics iodine-125 episcleral plaque therapy using modern biopsy techniques and intraoperative ultrasound guidance at our institution. METHODS AND MATERIALS: A retrospective chart review was conducted for 48 consecutive patients with uveal melanoma who were treated with Eye Physics plaque brachytherapy performed by 1 ocular oncologist. All patients underwent intraoperative ultrasound for image guidance of plaque placement. A dose of 85 Gy was prescribed to the apical height of the tumor or 5 mm from the inner sclera, whichever was greater. Forty-five patients underwent biopsy. Visual acuity, complication data, and recurrence rates were recorded. RESULTS: Median age at presentation was 63.0 years (range, 19-86 years). Median follow-up was 21.6 months. Median tumor apical height was 3.3 mm (range, 1.8-11.5 mm). Median dose at apex for tumor height >5 mm was 85.0 Gy and 142.5 Gy for tumor height ≤5 mm. Mean percent decrease in tumor height from baseline at 12, 24, and 36 months was 39.6%, 51.8%, and 53.8%, respectively. At 24 months, 19/23 (82.6%) patients maintained vision within 3 lines of baseline visual acuity. Twelve patients developed radiation retinopathy, 6 of whom were treated with anti-vascular endothelial growth factor therapy in the context of a clinical trial. No patients to date have local failure. Three patients are alive with confirmed hepatic metastases. CONCLUSIONS: We reported 0% early local failure rate and steady reduction in tumor height in 48 patients with uveal melanoma, ranging from small to large size, who were treated with Eye Physics iodine-125 episcleral plaque therapy using intraoperative ultrasound guidance. This promising result emphasizes the importance of image guided brachytherapy with intraoperative ultrasound at the time of plaque placement.
Authors: Jay A Messer; Raed J Zuhour; Waqar Haque; Gary D Lewis; Amy C Schefler; Andrew Wong; Eric H Bernicker; Patricia Chevez-Barrios; Enzhuo Michelle Quan; Andrew Farach; E Brian Butler; Sandra S Hatch; Bin S Teh Journal: J Contemp Brachytherapy Date: 2020-08-21
Authors: Andrew J Wong; Bin S Teh; Brandon T Nguyen; Ramiro Pino; Maria E Bretana; Eric H Bernicker; Patricia Chevez-Barrios; E Brian Butler; Amy C Schefler Journal: J Contemp Brachytherapy Date: 2022-04-11
Authors: Neil Chevli; Raed J Zuhour; Jay A Messer; Waqar Haque; Amy C Schefler; Eric H Bernicker; Patricia Chevez-Barrios; Andrew M Farach; E Brian Butler; Bin S Teh Journal: J Contemp Brachytherapy Date: 2022-04-02